Detection of Circulating Tumor Cells in Patients With Sarcomas (CTCS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02983539|
Recruitment Status : Recruiting
First Posted : December 6, 2016
Last Update Posted : July 2, 2018
The sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and 10% in children. Even though it is a rare cancer, it contributes to a significant loss of years of life in comparison with other types of cancer, due the fact that it affects children and young people. The diagnosis and treatment are difficult, considering the diversity and rarity of this disease. In addition, on average, more than 50% of patients with high-grade sarcoma present tumor relapse and distant recurrence is considered the main cause of death. The presence of Circulating Tumor Cells (CTCs) in the blood of patients with sarcoma may be an early marker of tumor invasion, because it is known that the CTCs circulate in the blood for months or years before the development of metastases. The CTCs can be used to monitor the response of the tumor to treatment, in order to match time, dose, and type of therapy.
Objectives: collect blood from patients with different types of sarcoma (leiomyosarcoma, synovial sarcoma, pleomorphic sarcoma and liposarcoma) in order to isolate and quantify CTCs. The investigators also have an intention to identify genes of resistance to treatment in these cells.
|Condition or disease|
|Leiomyosarcoma Pleomorphic Liposarcoma Synovial Sarcoma Liposarcoma|
Methodology: This is a prospective study, to be made by whole blood collection from 40 patients with different types of sarcomas (leiomyosarcoma, pleomorphic sarcoma, synovial sarcoma and liposarcoma). The collections will be made in three different moments: before the beginning of the treatment, during and at the end of this (8 mL). Blood samples will be processed and filtered on ISET system for the isolation and quantification of CTCs. Later, it will be performed immunocytochemistry (ICQ) single and/or double staining for protein assessment. The following proteins will be assessed: CD45, MRP1, MRP2 and MRP7.
Expected Results: The investigators hope that this study can show if the CTCs can be used as "liquid biopsy" in patients with leiomyosarcoma, synovium and pleomorphic sarcoma and liposarcoma.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Detection of Circulating Tumor Cells in Patients With Metastatic Sarcomas|
|Study Start Date :||October 2015|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||June 2018|
- progression free survival [ Time Frame: 6 months ]time to first progression until the second one
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02983539
|Contact: Ludmilla Chinen, PhD||55 11 21895000 ext email@example.com|
|ACCamargo Cancer Center||Recruiting|
|Sao Paulo, SP, Brazil, 01509900|
|Contact: Ludmilla Chinen, PhD 1121895000 ext 2776 firstname.lastname@example.org|
|Principal Investigator: Ludmilla Chinen, PhD|
|Principal Investigator:||Ludmilla Chinen, PhD||AC Camargo Cancer Center|